Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Cancer-associated mutations reveal a novel role for EpCAM as an inhibitor of cathepsin-L and tumor cell invasion

Fig. 1

Cancer-associated EpCAM mutations. Histogram (top) shows location and frequency of EpCAM cancer-associated mutations as reported in COSMIC (https://cancer.sanger.ac.uk/cosmic). Protein schematic (bottom) indicates EpCAM protein structure. EpCAM is a type-1 transmembrane protein with a signal peptide (SP, green), an N-terminal domain (ND, blue), a thyroglobulin type-1 domain (TY-1, red), a C domain (CD, tan), a transmembrane domain (TM, gray), and an intracellular domain (EpIC, purple). Domain positions noted as reported by Pavsic et al. [10]. The EpCAM C66Y mutation in the TY-1 domain is predicted to be highly damaging by Polyphen2 (http://genetics.bwh.harvard.edu/pph2/)

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us